Corvus Pharmaceuticals, Inc. ( CRVS) - Key Metrics
CRVS Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0 | -$0.19 | -$0.17 | -$0.17 |
| 2026Q1 | $0 | -$0.15 | -$0.12 | -$0.12 |
| 2025Q4 | $0 | -$0.16 | -$0.12 | -$0.12 |
| 2025Q3 | $0 | -$0.12 | -$0.12 | -$0.12 |
| 2025Q2 | $0 | -$0.10 | -$0.07 | -$0.08 |
CRVS Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -19.66 |
| 2026Q1 | 0% | -24.38 |
| 2025Q4 | 0% | -10.69 |
| 2025Q3 | 0% | -15.35 |
| 2025Q2 | 0% | -10 |
CRVS
Price: $14.89
52 week price:
Earnings Per Share: -0.64 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 47000
Ebitda: -12.7 millionMarket Capitalization: 1.2 billion